CELCC 2014 Astract
P6. Induction chemo- or chemoradiotherapy followed by resection for N2 positive NSCLC—a retrospective study
Olivia Foesleitner1, Thomas Klikovits1, Mir Alireza Hoda1, Robert Pirker2, Sabine Zoechbauer2, Karin Dieckmann3, Helmut Prosch4, Madleine Arns5, Peter Schenk5, Walter Klepetko1
1Division of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 2Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 3Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 4Department of Radiology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 5Department of Pneumologie, LKH Hochegg, Hochegg, Austria
Background: Advanced stage non-small cell lung cancer (NSCLC) is a fatal disease, characterized by mediastinal lymph node involvement (N2) and/or locally advanced tumor. In these patients the role of surgical resection—combined with induction treatment—remains controversial. We aimed to assess the clinical outcome of patients undergoing induction chemo- or chemoradiotherapy for N2 positive NSCLC.
Methods: We retrospectively reviewed the medical files of all consecutive patients undergoing induction chemo- or chemoradiotherapy followed by curative resection for N2 positive NSCLC between 1998 and 2013 at our institution.
Results: A total of 79 patients with N2 positive NSCLC received induction chemo- (n=36, 46%) or chemoradiotherapy (n=43, 54%) followed by radical surgery. The patients comprised 57 (72%) men and 22 (28%) women with a mean age of 58.5 years at the time of resection. Five sublobar resections, 44 lobectomies, five bilobectomies, and 25 pneumonectomies were performed. In 74 (93%) patients a complete resection (R0) was achieved. The 30-day morbidity and mortality were 26% and 1.3%. Overall 3- and 5-year survival rates were 66% and 54%, respectively. Overall disease free survival (DFS) will be presented at the conference. There was no difference in survival between patients receiving induction chemo- or chemoradiation (P=0.29).
Conclusions: Within a trimodality therapy including radical surgery favorable results for selected patients with N2 positive NSCLC can be achieved. Further prospective randomized trials are needed in order to investigate the value of radical resection in these patients.
Keywords: Non-small cell lung cancer (NSCLC); chemoradiotherapy; mediastinal lymph nodes
doi: 10.3978/j.issn.2218-6751.2014.AB018
Cite this article as: Foesleitner O, Klikovits T, Hoda MA, Pirker R, Zoechbauer S, Dieckmann K, Prosch H, Arns M, Schenk P, Klepetko W. Induction chemo- or chemoradiotherapy followed by resection for N2 positive NSCLC—a retrospective study. Transl Lung Cancer Res 2014;3(5):AB018. doi: 10.3978/j.issn.2218-6751.2014.AB018
